Pharmaceutical Giants Defy Yield Trap Fears, Offer Promising Buys

As of November 14th, 2025, pharmaceutical giants Bristol Myers Squibb, Pfizer, and Dentsply Sirona are defying the notion of a "yield trap" and may offer promising buying opportunities for investors. While these companies have high dividend yields, their current stock prices may not fully reflect their growth potential.

Bristol Myers Squibb, in particular, has been trading at a low valuation of only 7.5 times forward earnings estimates, with a forward dividend yield of around 5.3%. This low price may be due to the company's past struggles, as many of its blockbuster drugs have faced competition from generics. However, Bristol Myers Squibb's "growth portfolio" appears to be helping counter these declines. In the most recent quarter, the company reported a 3% increase in sales and adjusted earnings that exceeded analysts' estimates.

Looking ahead, Bristol Myers Squibb's success with in-demand products like Breyanzi and Reblozyl could result in further improvements to its revenue and earnings growth. Meanwhile, the company has steadily raised its dividend each year since 2010, providing investors with a steady stream of returns.

Similarly, Pfizer and Dentsply Sirona, despite their poor near-term track records of price performance, may also prove to be worthwhile investments at their current prices. Investors should not assume that a high dividend yield is always a red flag, as these pharmaceutical companies may offer compelling long-term value.